Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung

Inventors

Guiducci, Cristiana • Coffman, Robert L.

Assignees

Dynavax Technologies Corp

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10111899-B2

Patent

Publication Date

2018-10-30

Expiration Date


Abstract

The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.

Core Innovation

The disclosure describes isolated polynucleotides identified as D60-7, D60-8, and D60-9 comprising at least one phosphorothioate internucleotide linkage. The polynucleotide D60-7 induces a lower maximal IFN-́ response and reduced pulmonary toxicity relative to D60-1 while retaining comparable in-vitro potency. Related subject matter encompasses corresponding polynucleotide compositions as well as pulmonary delivery formats.

Intrapulmonary administration of D60-7 induces local cytokines with decreased lung histopathology and reduced weight loss in murine models. Furthermore, combination of D60-7 with anti-PD-1 enhances survival outcomes and reduces pulmonary metastases in a 4T1 model. Background problem information is not explicitly disclosed in the provided content.

Claims Coverage

The relevant claims identify one independent claim directed to an isolated polynucleotide, with dependent claims reciting specific linkages, compositions, and kits.

Isolated polynucleotide with a phosphorothioate linkage

The isolated polynucleotide consists of SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9, and comprises at least one phosphorothioate internucleotide linkage.

The independent claim covers the designated isolated polynucleotide sequences containing at least one phosphorothioate linkage, while dependent claims further define all-phosphorothioate linkages, pharmaceutical compositions, and kits.

Stated Advantages

D60-7 exhibits a lower maximal IFN-́ induction and reduced pulmonary toxicity compared to D60-1 while maintaining comparable in-vitro potency.

Intrapulmonary D60-7 administration results in less lung histopathology and reduced weight loss in mouse studies.

Combination of D60-7 with anti-PD-1 improves survival and decreases lung metastases in the 4T1 model.

Documented Applications

Pulmonary delivery and intrapulmonary administration of the isolated polynucleotide.

Kits comprising instructions for using the pharmaceutical composition to treat cancer in a mammalian subject.

Combination therapy with anti-PD-1 in a 4T1 metastatic tumor model.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.